Stock Market Reviews

OM (Outset Medical, Inc.) News

Get the latest news, insights, and market updates on OM (Outset Medical, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Outset Medical (OM): Assessing Valuation After Q3 Miss, Sales Leadership Exit, and Steep Stock Drop
  Outset Medical (OM) delivered third-quarter results that fell short of expectations and lowered its full-year revenue outlook, attributing the performance to delays in closing large enterprise deals as well as the recent exit of its Head of Sales. See our latest analysis for Outset Medical. Shares of Outset Medical dropped hard after its latest results, with a 1-day share price return of -48% capping off a steady slide this year as investors reacted to lower guidance and changes in sales...
  Nov 12, 2025 - $OM
• Outset Medical Inc (OM) Q3 2025 Earnings Call Highlights: Navigating Growth and Challenges
  Despite revenue guidance adjustments, Outset Medical Inc (OM) shows strong market demand and improved margins.
  Nov 11, 2025 - $OM
• SoftBank Sale of Nvidia Stake Weighs on Tech Sector, Driving Mixed Premarket Action for US Equity Futures
  US equity futures were mixed ahead of Tuesday's opening bell, with futures of technology sector-heav
  Nov 11, 2025 - $OM
• Outset Medical, Inc. (OM) Reports Q3 Loss, Lags Revenue Estimates
  Outset Medical (OM) delivered earnings and revenue surprises of -7.81% and -3.19%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 10, 2025 - $OM
• Outset Medical Reports Third-Quarter Results
  SAN JOSE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2025 and revised its 2025 revenue guidance. Third Quarter and Recent Highlights Net revenue of $29.4 million grew 3% from the prior year period, driven by an 8% increase in Tablo console revenue.Recurring revenue consist
  Nov 10, 2025 - $OM
• 10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates
  10x Genomics (TXG) delivered earnings and revenue surprises of +18.52% and +4.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 6, 2025 - $OM
• Outset Medical to Present at the 2025 Stifel Healthcare Conference
  SAN JOSE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 2025 Stifel Healthcare conference on Wednesday, November 12, 2025, at 10:40 a.m. Eastern time. A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https://
  Nov 5, 2025 - $OM
• New Research Demonstrates the Advantages of an Insourced Dialysis Service Line for Acute-Care Facilities Using Outset Medical’s Tablo® Hemodialysis System
  Data from over 1 Million Tablo Treatments Among the Findings Presented at the American Society of Nephrology’s Kidney Week 2025SAN JOSE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced new research findings from over 1 million Tablo hemodialysis treatments across approximately 750 facilities, and 5-year results from the inso
  Nov 5, 2025 - $OM
• Outset Medical to Report Third Quarter 2025 Financial Results on Monday, November 10, 2025
  SAN JOSE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter 2025 after the close of trading on Monday, November 10, 2025. On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Fina
  Oct 27, 2025 - $OM
• Tempus (TEM) Stock Jumps 13.6%: Will It Continue to Soar?
  Tempus (TEM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
  Sep 12, 2025 - $OM